News
Public · Published
Canaccord Genuity maintains Viking Therapeutics at Buy, raises price target to $118 from $106
Canaccord Genuity kept its Buy rating on Viking Therapeutics and raised its price target to $118 from $106. The new target is 11.3% higher than the previous one and implies 332.6% upside from the October 30 closing price of $27.28.
Published:
Updated:
What happened
Canaccord Genuity kept its Buy rating on Viking Therapeutics and raised its price target to $118 from $106. The new target is 11.3% higher than the previous one and implies 332.6% upside from the October 30 closing price of $27.28.
Confirmed
Global impact / market context
A higher target signals that Canaccord sees more potential value in Viking shares, which may shape investor expectations and trading decisions. However, a price target is an analyst estimate, not a guaranteed share price, and the article gives no company results or business changes supporting the revision.
Analyst inference
The article lists recent Buy ratings from Canaccord Genuity and Truist Securities, with earlier targets of $106 and $85. Canaccord’s new $118 target is above those figures, but analyst estimates can differ and do not establish future performance.
Confirmed
What to watch
- Check whether Canaccord publishes further updates explaining its higher target, since the article does not state what assumptions or company developments drove the change. Analyst inference
- Compare any future Viking Therapeutics results or business updates with the analyst outlook; changes in expected revenue, costs, or development spending could alter the case for the target. Analyst inference
- The article reports three recent analyst notes with targets from $85 to $106; Canaccord’s new $118 target is higher than that earlier range. Confirmed
Evidence
- Original source link unavailable